Piramal Pharma Limited (PPL) reported a robust financial performance for the fiscal year ended March 31, 2025, with net profit rising over 411% to ₹91 crore, as compared to ₹18 crore in FY24. The growth was driven by strong momentum in its Contract Development and Manufacturing Organization (CDMO) business and operational efficiency across verticals.
The company’s revenue from operations stood at ₹9,151 crore, marking a 12% year-on-year growth, while EBITDA increased by 15% to ₹1,580 crore. EBITDA margin remained steady at 17%. For the fourth quarter (Q4FY25), revenue rose 8% YoY to ₹2,754 crore, with net profit at ₹154 crore, up from ₹101 crore in the same period last year.
CDMO leads the performance; quality track record maintained
The CDMO segment, which includes commercial manufacturing of on-patent molecules, clocked a 15% annual revenue growth to ₹5,447 crore. The business benefited from increased innovation-related work, which rose to 54% of CDMO revenues, and over 50% YoY growth in commercial revenues.
The company cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations, reinforcing its zero OAI (Official Action Indicated) status maintained since 2011.
Strong showing in generics and consumer healthcare
The Complex Hospital Generics (CHG) business, with revenue of ₹2,633 crore, saw a notable boost from inhalation anesthetics and Baclofen. The company retained its #1 position in the US market for Sevoflurane, with a 44% share.
The India Consumer Healthcare (ICH) segment crossed a strategic revenue milestone of ₹1,000 crore, with power brands contributing 49% of total ICH revenue. The company launched 21 new products and 31 new SKUs during the year, and e-commerce sales surged 39% YoY.
Balance sheet healthy; net debt under control
PPL maintained a Net Debt to EBITDA ratio of 2.7x, well below its previous 5.6x level. Net debt declined to ₹4,199 crore, from ₹3,932 crore in FY24. The company also reported a total equity of ₹8,125 crore.
Looking ahead: Innovation and scale
Chairperson Nandini Piramal said FY25 was “a steady year for the company,” highlighting performance across all business segments and reiterating the company’s ambition to become a $2 billion revenue company with 25% EBITDA margins and high return on capital employed (ROCE). “We crossed $1 billion in revenues with 12% YoY growth and 5x increase in net profits. Our focus on innovation, operational excellence, and expansion in the US and emerging markets has placed us on a strong trajectory for sustainable growth,” she added.
